

## SUPPORTING INFORMATION

### **Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3**

Shi-Fi Liang,<sup>a</sup> Fang-Fang Zuo,<sup>a</sup> Bin-Cheng Yin,<sup>\*abc</sup> and Bang-Ce Ye<sup>\*ab</sup>


<sup>a</sup>Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, Zhejiang, China

<sup>b</sup>Lab of Biosystem and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China


<sup>c</sup>School of Chemistry and Chemical Engineering, Shihezi University, Shihezi 832000, Xinjiang, China

\*Corresponding author: Bin-Cheng Yin, Email: [binchengyin@ecust.edu.cn](mailto:binchengyin@ecust.edu.cn); Bang-Ce Ye, Email: [yebangce@zjut.edu.cn](mailto:yebangce@zjut.edu.cn) or [bcye@ecust.edu.cn](mailto:bcye@ecust.edu.cn).


## Supporting figures




**Figure S1.** TEM images of Exo-An2 and Exo (scale bar is 200 nm). Exo-An2 and Exo showed saucer-cup morphology.




**Figure S2.** Flow cytometry analysis of internalization of Exo derived from THP-1 and M1 macrophages by U87MG. Exosomes derived from M1 macrophages exhibited the higher uptake efficiency than exosomes derived from THP-1.




**Figure S3.** Mass spectrum of An2. The peak of An2 is clearly seen at  $m/z$  1203.05.




**Figure S4.** PAGE gel analysis for the detection of siRNA. siRNA was encapsulated to exosomes, and Exo-siRNA was sonicated for 30 min to release siRNA. Then Exo-siRNA (0.1 nmol siRNA) and 0.1 nmol siRNA and 10  $\mu$ L exosomes were loaded on 20% TBE PAGE gel and electrophoresed (90 V, 180 min) in TBE running buffer. After electrophoresis, the gel was stained by 2.5  $\mu$ L SYBR gold in 25 mL TBE buffer for 30 min, followed by detection using ChemiScope 6000. siRNA and Exo were used as control.




**Figure S5.** The average particle size and zeta-potential of Exo-An2 and Exo determined by nanoparticle tracking analysis. The average particle size and zeta-potential of Exo-An2 were similar to those of Exo. Values represent means  $\pm$  SD (n = 3).




**Figure S6.** Stability of siRNA loaded with or without Exo in human plasma. Lane 1: Exo-An2-siRNA was incubated with plasma for 24 h; Lane 2: siRNA was incubated with plasma for 24 h; Lane 3: Exo-An2-siRNA; Lane 4: siRNA. The PAGE gel demonstrates that Exo-An2 effectively protects the siRNA from plasma RNase degradation.




**Figure S7.** Release profiles of total FAM-tagged siRNA from Exo-An2 determined by incubation for up to 28 h in PBS (pH 7.4). Approximate 75% of the encapsulated siRNA was gradually released within 21 h. Values represent means  $\pm$  SD (n = 3).



**Figure S8.** Confocal images of U87MG incubated with Exo and Exo-An2 for 4 h (scale bar is 10  $\mu$ m). Exosomes and cell nucleus were labeled with a red fluorescent dye (DiD) and DAPI respectively (red: exosome, blue: cell nucleus). Confocal images reveal that conjugation of An2 on the surfaces of the exosomes could promote internalization of exosomes.



**Figure S9.** Flow cytometry analysis of apoptotic effect of PBS, Exo, siRNA, Exo-siRNA and Exo-An2-siRNA. U87MG were treated with PBS, Exo, siRNA, Exo-siRNA and Exo-An2-siRNA for 48 h. The apoptotic percentage of U87MG treated with Exo-An2-siRNA reached around 94.55%, which was much higher than that of U87MG treated with Exo-siRNA (10.09%), PBS (4.46%), Exo (3.99%), and siRNA (7.5%).



**Figure S10.** H&E in the major organs from mice receiving the PBS and Exo-An2-siRNA treatment. The mice injected with PBS were used as a control (scale bar is 200  $\mu\text{m}$ ). Compared to the PBS group, the major organs did not exhibit any damage in the Exo-An2-siRNA group.